[an error occurred while processing this directive]

Relationship between serum metabolomics and stenosis in autologous arteriovenous fistula in maintenance hemodialysis patients

  • LIAO Lu ,
  • ZOU Li-Ting ,
  • FU Meng-Ru ,
  • YAN Yan ,
  • XIAO Jun
Expand
  • Department of Nephrology, The First Affiliated Hospital of Nanchang University, Nanchang 330006, China

Received date: 2022-09-22

  Revised date: 2022-12-27

  Online published: 2023-03-03

Abstract

With the increasing incidence of chronic kidney disease (CKD) stage 5, the number of patients with maintenance hemodialysis (HD) is increasing. Autogenous Arteriovenous fistula (AVF) is the preferred method for long-term vascular access in HD patients. AVF stenosis is the main cause of AVF dysfunction in HD patients, and its mechanism has not been fully elucidated. CKD5 patients often cause various related complications due to changes in the types and concentrations of blood metabolites. The application of metabolomics technology has revealed various metabolic disorders in CKD patients. This article analyzes the correlation between abnormal blood metabolomics and AVF stenosis in CKD patients, hoping to provide new ideas for elucidating the mechanism of AVF stenosis and prevention and treatment of AVF stenosis

Cite this article

LIAO Lu , ZOU Li-Ting , FU Meng-Ru , YAN Yan , XIAO Jun . Relationship between serum metabolomics and stenosis in autologous arteriovenous fistula in maintenance hemodialysis patients[J]. Chinese Journal of Blood Purification, 2023 , 22(03) : 206 -209 . DOI: 10.3969/j.issn.1671-4091.2023.03.011

References

[1]Yongchun H, Hua J, Xiaohan H, et al.Solutions to stuck tunneled cuffed catheters in patients undergoing maintenance hemodialysis[J].The Journal of Vascular Access, 2021, 22(2):203-208
[2]Rothuizen T C, Wong C, Quax P H, et al.Arteriovenous access failure: more than just intimal hyperplasia?[J].Nephrol Dial Transplant, 2013, 28(5):1085-1092
[3]许倬, 李娇, 张利, 等.代谢组学在慢性肾脏病生物标志物临床研究中的应用[J].中华肾病研究电子杂志, 2018, 7(5):224-230
[4]Meijers B, Evenepoel P, Anders H J.Intestinal microbiome and fitness in kidney disease[J].Nat Rev Nephrol, 2019, 15(9):531-545
[5]Hammes M.Hemodynamic and Biologic Determinates of Arteriovenous Fistula Outcomes in Renal Failure Patients[J]. BioMed research international, 2015, 2015:171674-171677. DOI:10.1155/2015 /171674.[J].BioMed research international, 2015, :171674-171677
[6]Browne L D, Bashar K, Griffin P, et al.The Role of Shear Stress in Arteriovenous Fistula Maturation and Failure:A Systematic Review[J].PloS one, 2015, 10(12):e0145795-
[7]Viecelli A K, Mori T A, Roy-Chaudhury P, et al.The pathogenesis of hemodialysis vascular access failure and systemic therapies for its prevention: Optimism unfulfilled[J].Seminars in dialysis, 2018, 31(3):244-257
[8]Salmela B, Hartman J, Peltonen S, et al.Thrombophilia and Arteriovenous Fistula Survival in ESRD[J].Clinical journal of the American Society of Nephrology, 2013, 8(6):962-968
[9]Ma S, Duan S, Liu Y, et al.Intimal Hyperplasia of Arteriovenous Fistula[J]. Ann Vasc Surg, 2022:1–10.DOI:org/10. 1016/j.avsg.2022.04.030.[J].Ann Vasc Surg, 2022, :1-10
[10]Riella M C, Roy-Chaudhury P.Vascular access in haemodialysis: strengthening the Achilles’ heel[J].Nature reviews. Nephrology, 2013, 9(6):348-357
[11]Bilgic M A, Yilmaz H, Bozkurt A, et al.Relationship of late arteriovenous fistula stenosis with soluble E-selectin and soluble EPCR in chronic hemodialysis patients with arteriovenous fistula[J].Clin Exp Nephrol, 2015, 19(1):133-139
[12]Lee T, Ul Haq N.New Developments in Our Understanding of Neointimal Hyperplasia[J].Advances in Chronic Kidney Disease, 2015, 22(6):431-437
[13]Pi X, Xie L, Patterson C.Emerging roles of vascular endothelium in metabolic homeostasis[J].Circ Res, 2018, 123(4):47-
[14]Brunet P, Gondouin B, Duval-Sabatier A, et al.Does Uremia Cause Vascular Dysfunction[J].Kidney & blood pressure research, 2011, 34(4):284-290
[15]Lee T, Chauhan V, Krishnamoorthy M, et al.Severe venous neointimal hyperplasia prior to dialysis access surgery[J].Nephrol Dial Transplant, 2011, 26(7):2264-2270
[16]Wasse H, Huang R, Naqvi N, et al.Inflammation,oxidation and venous neointimal hyperplasia precede vascular injury from AVF creation in CKD patients[J].The journal of vascular access, 2012, 13(2):168-174
[17]Weiss M F, Scivittaro V, Anderson J M.Oxidative stress and increased expression of growth factors in lesions of failed hemodialysis access[J]. Am J Kidney Dis. 2001, 37:970-980.DOI:10.1053/ajkd.2001. 23618.[J].Am J Kidney Dis, 2001, (37):970-980
[18]Gagnebin Y, Julien B, Belén Pet, et al.Metabolomics in chronic kidney disease: Strategies for extended metabolome coverage[J]. Journal of pharmaceutical and biomedical analysis, 2018, 161:313-325.DOI:10.1016/j.jpba.2018.08.046.[J].Journal of pharmaceutical and biomedical analysis, 2018, (161):313-325
[19]Haggarty J, Burgess K E.Recent advances in liquid and gas chromatography metho-dology for extending coverage of the metabolome. Curr Opin Biotechnol[J], 2017, 43:77-85. DOI:10.1016/j.copbio.2016.09. 006.[J].Curr Opin Biotechnol, 2017, (43):77-85
[20]Hocher B, Adamski J.Metabolomics for clinical use and research in chronic kidney disease[J].Nat Rev Nephrol, 2017, 13(5):269-284
[21]Aron-Wisnewsky J, Clément K.The gut microbiome, diet, and links to cardiometabolic and chronic disorders[J]. Nat Rev Nephrol, 2016; 12(3):169-181. DOI:10.1038/nrneph.2015.191.[J].Nat Rev Nephrol, 2016, 12(3):169-181
[22]Wang X, Yang S, Li S, et al.Aberrant gut microbiota alters host metabolome and impacts renal failure in humans and rodents[J].Gut, 2020, 69(12):2131-2142
[23]Yang T, Richards E M, Pepine C J, et al.The gut microbiota and the brain-gut-kidney axis in hypertension and chronic kidney disease[J].Nat Rev Nephrol, 2018, 14(7):442-456
[24]Mika A, Wojtowicz W, Z?bek A, et al.Application of nuclear magnetic resona-nce spectroscopy for the detection of metabolic disorders in patients with moderate kidney insufficiency[J]. Journal of pharmaceutical and biomedical analysis, 2018, 149:1-8. DOI:10.1016/jjp ba.2017.10.037.[J].Journal of pharmaceutical and biomedical analysis, 2018, (149):1-8
[25]Chen D, Cao G, Chen H, et al.Identification of serum metabolites associating with chronic kidney disease progression and anti-fibrotic effect of 5-methoxytryptop-han[J].Nature Comm- unications, 2019, 10(1):1476-
[26]Wu I W, Hsu K H, Lee C C, et al.p-Cresyl sulphate and indoxyl sulphate predict progression of chronic kidney disease[J].Nephrol Dial Transplant, 2011, 26(3):938-947
[27]Koenig P, Nagl C, Neurauter G, et al.Enhanced degradation of tryptophan in patients on hemodialysis[J].Clin Nephrol, 2010, 74(6):465-470
[28]Duranton F, Lundin U, Gayrard N, et al.Plasma and urinary amino acid metabolomic profiling in patients with different levels of kidney function[J].Clin J Am Soc Nephrol, 2014, 9(1):37-45
[29]Missailidis C, H?llqvist J, Qureshi AR, et al.Serum Trimethylamine-N-Oxide Is Strongly Related to Renal Function and Predicts Outcome in Chronic Kidney Disease[J].PloS One, 2016, 11(1):e0141738-
[30]Bain M A, Faull R, Fornasini G, et al.Accumulation of trimethylamine and trimethylamine-N-oxide in end-stage renal disease patients undergoing haemodialysis[J].Nephrol Dial Transplant, 2006, 21(5):1300-1304
[31]杜怡, 王玲, 贾洁爽, 等.慢性肾脏病肠道微生态异常致相关代谢产物变化及器官损害[J].中华肾脏病杂志, 2019, 35(2):155-160
[32]Jadoon A, Mathew A V, Byun J, et al.Gut Microbial Product Predicts Cardiovas- cular Risk in Chronic Kidney Disease Patients[J].American journal of nephr- ology, 2018, 48(4):269-277
[33]Yao Y, Cai X, Fei W, et al.The role of short-chain fatty acids in immunity, inflammation and metabolism[J].Crit Rev Food Sci Nutr. 2022, 62(1):1-12.DOI: 10.1080/10408398.2020.1854675.[J].Crit Rev Food Sci Nutr, 2022, 62(1):1-12
[34]Chu L, Zhang K, Zhang Y, et al.Mechanism underlying an elevated serum bile acid level in chronic renal failure patients[J].International urology and nephrology, 2014, 47(2):345-351
[35]Zhu S, Zhang F, Shen A, et al.Metabolomics Evaluation of Patients With Stage 5 Chronic Kidney Disease Before Dialysis, Maintenance Hemod- ialysis, and Peritoneal Dialysis [J]. Frontiers in Physiology, 2021, 11: 630646. DOI:10.3389/fphys.2020.630646.[J]. Frontiers in Physiology, 2021, (11):630-646
[36]Kolachalama V B, Shashar M, Alousi F, et al.Uremic Solute-Aryl Hydrocarbon Receptor-Tissue Factor Axis Associates with Thrombosis after Vascular Injury in Humans[J].Journal of the American Society of Nephrology, 2018, 29(3):1063-1072
[37]Takada T, Yamamoto T, Matsuo H, et al.Identification of ABCG2 as an Exporter of Uremic Toxin Indoxyl Sulfate in Mice and as a Crucial Factor Influencing CKD Progression[J].Scientific reports, 2018, 8(1):11147-11149
[38]Qi X, Zhang Y, Gao J, et al.Metabolite profiling of hemodialysate using gas chromatography time-of-flight mass spectrometry[J].J Pharm Biomed Anal, 2011, 55(5):1142-1147
[39]Gagnebin Y, Jaques D A, Rudaz S, et al.Exploring blood alterations in chronic kidney disease and haemodialysis using metabolomics[J].Scientific Reports, 2020, 10(1):19502-
[40]Tsalik E L, Willig L K, Rice B J, et al.Renal systems biology of patients with systemic inflammatory response syndro- me[J].Kidney International, 2015, 88(4):804-814
[41]Sumida K, Kovesdy C P.The gut -kidney-heart axis in chronic kidney disease[J].Physiology international, 2019, 106(3):195-206
[42]Tang W H, Kitai T, Hazen S L.Gut Microbiota in Cardiovascular Health and Disease[J].Circulation Research, 2017, 120(7):1183-1196
[43]Feng Y, Cao G, Chen D, et al.Microbiome–metabolomics reveals gut microbiota associated with glycine- conjugated metabolites and polyamine metabolism in chronic kidney disease[J].Cellular and Molecular Life Sciences, 2019, 76(24):4961-4978
[44]Nigam S K, Bush K T.Uraemic syndrome of chronic kidney disease: altered remote sensing and signallingNature reviews[J].Nephrology, 2019, 15(5):301-316
[45]Li Y, Lu X, Wang J, et al.Metabonomic study of the fruits of Alpinia oxyphylla as an effective treatment for chronic renal injury in rats[J]. Journal of pharma- ceutical and biomedical analysis, 2016, 124:236-245.DOI:10.1016/j.jpba.2016.02.035.[J].Journal of pharma- ceutical and biomedical analysis, 2016, (124):236-245
[46]Günthner T, Jankowski V, Kretschmer A, et al.Endothelium and vascular smooth muscle cells in the context of uremia[J].Seminars in dialysis, 2009, 22(4):428-432
[47]Zhu W, Gregory J C, Org E, et al.Gut Microbial Metabolite TMAO Enhances Platelet Hyperreactivity and Thrombosis Risk[J].Cell, 2016, 165(1):111-124
[48] Kalim S, Rhee E P.An overview of renal metabolomics[J]. Kidney Int. 2017 Jan, 91(1):61-69.DOI:10.1016/j.kint.2016. 08.021.[J].Kidney Int, 2017, 91(1):61-69
[49]Altenbuchinger M, Zacharias H U, Solbrig S, et al.A multi-source data integration approach reveals novel associations between metabolites and renal outcomes in the German Chronic Kidney Disease study[J].Scientific Reports, 2019, 9(1):13954-
[50]Li R, Zeng L, Xie S, et al.Targeted metabolomics study of serum bile acid profile in patients with end-stage renal disease undergoing hemodialysis [J].PeerJ, 2019, 7:e7145.DOI:10.7717/peerj.7145.[J].PeerJ, 2019, (7):e7145-
[51]Chen W, Fitzpatrick J, Sozio S M, et al.Identification of Novel Biomarkers and Pathways for Coronary Artery Calcificatio-n in Nondiabetic Patients on Hemodialysis Using Metabolomic Profiling[J].Kidney, 2021, 2(2):279-
Outlines

/

[an error occurred while processing this directive]